Presentation Description

No description available.


By: vishalsasane111 (123 month(s) ago)

plz send me this ppt presentationon my mail - vishalsasane111@yahoo.in

By: pharmapavan55 (124 month(s) ago)

thanks to share this presentation...plz send me on my mail pharmapavan55@gmail.com

By: gahong (126 month(s) ago)

i would apprecaite your sharing. please send it to gahong@gmail.com

By: rubsa (127 month(s) ago)

Dear sir, plz send this ppt on my email id - shaileshmpharm@gmail.com. very useful for me

By: dhaval.kavathia (128 month(s) ago)

Dear sir, plz send this ppt on my email id dhaval.kavathia@gmail.com. very useful for me

See all

Presentation Transcript

New Drug Application(NDA) Vs Abbreviated new drug application (ANDA) : 

New Drug Application(NDA) Vs Abbreviated new drug application (ANDA) 1 Name: B.Vamsikrishna Reddy Year : M.Pharm (Pharmaceutics) College : Manipal College of Pharmaceutical Scieces(MCOPS), Manipal Email id: vamsikrishnareddy57@gmail.com Name: Sneya Priya Year : M.Pharm( Pharmaceutics) College: Manipal college of Pharmaceutical Scieces(MCOPS), Manipal Email id: snehpriya123@gmail.com

Contents : 

Contents 1.New Drug Application(NDA) a) Introduction. b) Goal of NDA c) Classification of NDA d) New drug development review e) The NDA in CTD Format 2. Abbreviated new drug application(ANDA) a) Introduction b) Goal of ANDA c )Patent certification condition 3. Conclusion.  4. References. 2

New Drug Application : 

New Drug Application Introduction Critical component for drug approval process which required to submit to USFDA before drug commercialization. The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA. Goal The NDA provide enough information to permit FDA reviewer to reach safety, efficacy and quality for pharmaceutical production 3

NDA Classifications : 

NDA Classifications New Molecular Entity New Salt of Previously Approved Drug (not a new molecular entity) New Formulation of Previously Approved Drug (not a new salt OR a new molecular entity) New Combination of Two or More Drugs Already Marketed Drug Product - Duplication (i.e., new manufacturer) New Indication (claim) for Already Marketed Drug (includes switch in marketing status from prescription to OTC) Already Marketed Drug Product - No Previously Approved NDA 4

New Drug Development and Review ProcessSteps from Test Tube to New Drug Application Review : 

New Drug Development and Review ProcessSteps from Test Tube to New Drug Application Review 5

Phases of clinical testing : 

Phases of clinical testing 6

Slide 7: 


Slide 8: 


NDA Review Process : 

NDA Review Process 9


NDA CONTENTS Section 1: Overall NDA index:- The NDA index is a comprehensive table of contents that enables the reviewers to find specific information in this massive document quickly. Section 2: Labeling It must include all draft labeling that is intended for use on the product container, cartons or packages, including the proposed package insert. 10

Slide 11: 

Section 3: Application summary Proposed annotated package insert Pharmacology class, scientific rational, intended use, and potential clinical benefits Foreign marketing history Chemistry, Manufacturing and control summary Nonclinical pharmacology and toxicology summary Human pharmacokinetics and bioavailability summary Microbiology summary Clinical data summary and results of statistical analysis Discussion of benefit/risk relationship 11

Slide 12: 

Section 4: Chemistry, manufacturing and controls Chemistry, manufacturing and control information Samples Methods validation package Section 5: Nonclinical pharmacology and toxicology Provide individual study reports, including pharmacology, toxicology, ADME studies. Effects related to the therapeutic indication, such as the pharmacodynamic ED50 in dose- ranging studies and the mechanism of act ion (if know n) Interactions with other drugs (or cross-reference the location of the information in any of the above subsection 12

Slide 13: 

Section 6: Human Pharmacokinetics and bioavailability includes data from Phase I safety and tolerance studies in healthy volunteers. Element in the section tabulated summary of studies showing all in vivo biopharmaceutics studies performed. Summary of analytical method used in in vivo biopharmaceutic study Pilot or background studies Bioavailibility or bioequivalence studies Pharmacokinetic studies In vitro studies 13

Slide 14: 

Section 7: Microbiology Includes for anti infective drug products. requires the following technical information and data:- A complete description of the biochemical basis of the drug action on microbial physiology The drugs antimicrobial spectrum Describe any known mechanism of resistance to the drug and provide information/data of any known epidemiologic studies demonstrating prevalence to resistance factor Clinical microbiology laboratory methods 14

Slide 15: 

Section 8: Clinical data Includes. List of investigators and list of INDs and NDAs Background or overview of clinical investigations Clinical pharmacology Controlled clinical trials Uncontrolled clinical trials Other studies and information Integrated summary of effectiveness data Integrated summary of safety information Drug abuse and overdose information Integrated summary of benefits and risks of drug 15

Slide 16: 

Section 9: Safety data Statements in draft labeling Contraindications Warnings Precautions Adverse events Section 10: Statistical data All controlled clinical trial reports Integrated efficacy and safety summaries Integrated summary of risks and benefits 16

Slide 17: 

Section 11: Case report tabulation include complete tabulation for each patient from every adequately are well controlled phase II and Phase III efficacy, clinical pharmacology study. It also tabulation of safety data from all clinical studies. Section 12: Case report forms include the complete CRF for each patient who died during a clinical study or adverse event, regardless of whether the AE is considered to be related to the study drug, even if the patient was receiving a placebo or comparative drug. 17

Slide 18: 

Application itself consists of a cover letter and a completed form FDA-356h along with several other supporting items as appropriate Item 13: Patent information Item 14: Patent certification Item 15: Establishment description Item 16: Debarment certification Item 17: Field copy certification Item 18: User fee cover sheet (Form FDA-3397) Item 19: Financial disclosure (Form FDA 3454, form FDA-3455) Item 20: Other/pediatric use 18

The NDA in CTD FormatModule 1 is not part of the CTD because it is not harmonized : 

The NDA in CTD FormatModule 1 is not part of the CTD because it is not harmonized 19


ANDA “A drug product that is comparable to a brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended use” It termed "abbreviated" because they generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Basic Generic Drug Requirements are:-- Same active ingredient(s) Same route of administration Same dosage form Same strength Same conditions of use Inactive ingredients already approved in a similar NDA 20

Goal of ANDA : 

Goal of ANDA To reduce the price of the drug. To reduce the time development. Increase the bioavailability of the drug in comparison to references list drug. 21

ANDA Review process : 

ANDA Review process 22

NDA vs. ANDA Review Process : 

NDA vs. ANDA Review Process NDA Requirement ANDA Requirement 23

What is Bioequivalence? : 

What is Bioequivalence? A generic drug is considered to be bioequivalent to the brand name drug if: The rate and extent of absorption do not show a significant difference from listed drug, or The extent of absorption does not show a significant difference and any difference in rate is intentional or not medically significant 24

Patent Certification condition for ANDA : 

Patent Certification condition for ANDA Described in section 505(j)(2)(A)(vii) of the Act. I Patent Not Submitted to FDA – Approval effective after OGD scientific determination II Patent Expired – Approval effective after OGD scientific determination III Patent Expiration Date (honored) – Tentative approval after OGD scientific determination, final approval when patent expires IV Patent Challenge – Tentative approval after OGD science determination, final approval when challenge won 25

Paragraph IV certification : 

Paragraph IV certification According to section 505(j)(2)(B)(i), 2157 CFR The ANDA applicant must provide appropriate notice of a paragraph IV certification to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA refers And by Section 505(j)(5)(B)(iv) An incentive for generic manufacturers to file paragraph IV certifications and to challenge listed patents as invalid, or not infringed, by providing for a 180-day period of marketing exclusivity 26

Patent Challenge Successful – Award of 180-Day Exclusivity Period : 

Patent Challenge Successful – Award of 180-Day Exclusivity Period Awarded to first ANDA holder to file a complete application with patent challenge Protection from other generic competition – blocks approval of subsequent ANDAs Protection triggered by: First commercial marketing Forfeiture provisions 27

Orphan Drug Exclusivity (ODE) : 

Orphan Drug Exclusivity (ODE) Orphan drug refers to a product that treats a rare disease - affecting fewer than 200,000 Americans 7 years exclusivity Granted on approval of designated orphan drug OGD works with the Office of Orphan Products 28

ANDA approval status : 

ANDA approval status 29




REFERENCES Douglas J. Pisano, David S. Manlus –FDA Regulatory Affairs, A guide for Prescription Drugs, Medical Devices and Biologics-New drug Application –Second edition-Marcel Dekker,inc- page no 69-108. Richard A. Guarino- New Drug Approval process-1)The New Drug Application, Content, Format 2) Abbreviated $ Supplementary New Drug Application- Fourth edition-Marcel Dekker,inc- page no 113-183. Loyd V. Allen Jr, Nicholas G. Popovich, Howard C. Ansel’s Pharmaceutical Dosage Forms and delivers systems- New Drug Development and Approval Process-8th edition- B.I. publication- Page no 25-65. http://www.fda.gov/cder/guidance/index.htm. 31

Slide 32: 

32 Thank u

authorStream Live Help